Lisette
Helene Deddens1, Peter A. Jarzyna2, Arjan W. Griffioen3,
Zahi A. Fayad2, Rick Michiel Dijkhuizen1, Willem JM
Mulder2
1Image Sciences Institute, University
Medical Center Utrecht, Utrecht, Netherlands; 2Imaging Science
Laboratories, Mount Sinai School of Medicine, New York, United States; 3Angiogenesis
Laboratory Amsterdam, VU Medical Center, Amsterdam, Netherlands
Nanoemulsions
represent an attractive delivery platform for hydrophobic compounds since
they improve their bioavailability and make their intravenous administration
possible. This abstract demonstrates that the nanoemulsion platform,
developed for passive delivery of hydrophobic compounds to tumor tissue, is
also very suitable for targeted applications. Data show the applicability of
αvβ3-specific RGD nanoemulsions in targeting tumor angiogenesis
visualized by MRI, fluorescence microscopy and immunohistochemistry.